Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2026--Veracyte, Inc.(Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market onThursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at4:30 p.m. Eastern Timeon the same day.

The conference call will be webcast live from the company’s website and will be available via the following link:https://edge.media-server.com/mmc/p/wwu2pyd7. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website athttps://investor.veracyte.com/events-presentations.

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care.Veracyte’s Diagnostics Platformcombines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continuedinnovation and pipeline development. The company’s portfolio includes theAfirma® Genomic Sequencing Classifier test,Decipher® Bladder Genomic Classifier test,Decipher® Prostate Genomic Classifier test,Prosigna® Breast Risk of Recurrence test, and theTrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’swebsiteor follow the company onLinkedInorX (Twitter).

View source version on businesswire.com:https://www.businesswire.com/news/home/20260709945913/en/

Source: Veracyte, Inc.